Enable Injections said yesterday that it entered a developmental partnership with Genentech for the Enable enFuse device.
Cincinnati-based Enable’s enFuse is an on-body drug delivery platform containing a drug transfer system compatible with syringes and vial containers. Currently, the enFuse is being developed for subcutaneous delivery of large volumes potentially rising to 50 mL.
The companies intend to combine for multiple molecule development programs with long-term manufacturing and supply arrangements to be made.
“Enable Injections is pleased to partner with Genentech in its focus on delivering patient-focused solutions,” said Enable founder, president & CEO Michael D. Hooven said in prepared remarks. “With the enFuse paired to deliver selected subcutaneous therapeutics, it can potentially benefit patients worldwide.”
Enable inked a developmental deal with Sanofi in June for the enFuse device and did the same with Apellis Pharmaceuticals and UCB in November 2018.
